Le Lézard
Classified in: Health
Subject: MRR

Outlook on the Cell Dissociation Global Market to 2028: Advancements in Non-Enzymatic Tissue Dissociation Presents Opportunities

DUBLIN, March 21, 2023 /PRNewswire/ -- The "Global Cell Dissociation Market by Product (Trypsin, Papain, DNase, Hyaluronidase, Instruments), Tissue Type (Connective Tissue, Epithelial Tissue), End-user (Pharma, Biopharma, Research Institutes) & Region - Forecast to 2028" report has been added to  ResearchAndMarkets.com's offering.

Research and Markets Logo

The global cell dissociation market is projected to grow from USD 0.6 billion in 2023 to USD 1.4 billion by 2028 at a CAGR of 17.8%.

The key factors driving the growth of the cell dissociation market are the increase in recombinant therapeutics sourced from mammalian cells, the growing focus on personalized medicine, and increasing GMP certification approvals for cell therapy production facilities. Additionally, advancements in non-enzymatic tissue dissociation are expected to offer lucrative market opportunities.

Enzymatic dissociation products segment to witness the highest growth during the forecast period

Based on product, the cell dissociation market is segmented into enzymatic dissociation agents, non-enzymatic dissociation agents, and instruments & accessories.

The enzymatic dissociation agents segment dominated the cell dissociation market in 2022. It is expected to hold the largest share till 2028. The expanding pool of operational entities in this segment and established protocols for using enzymatic dissociation agents are key contributors to market growth.

Non-enzymatic alternatives for cell dissociation are being developed to overcome the limitations of traditional enzymes. Instruments and accessories form a niche segment, with few manufacturers active.

Connective tissue segment to register the highest growth in the cell dissociation market during the forecast period

Based on tissue type, the cell dissociation market has been segmented into connective tissue, epithelial tissue, and other tissues (muscle tissue, lung tissue, and nerve tissue).

Connective tissue dominated the cell dissociation market in 2022. The extensive research on connective tissues has ensured a high share of this segment. However, the epithelial tissue segment is expected to grow at the highest rate over the forecast period.

Asia-Pacific is estimated to register the highest CAGR during the forecast period

The cell dissociation market is segmented into North America, Europe, the Asia-Pacific (APAC), Latin America, and the Middle East & Africa (MEA).

The Asia-Pacific market is estimated to register the highest growth during the forecast period primarily due to the rising R&D investments in the pharmaceutical sectors of several emerging APAC countries, favorable regulatory guidelines & government support, lower manufacturing costs, and increasing incidence of diseases.

Market Dynamics





Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/qwcew

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470 
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716 

Logo:  https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg 

SOURCE Research and Markets

These press releases may also interest you

at 14:20
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced results from a retrospective analysis of the interventional PATHFINDER study to assess whether diagnostic evaluations of individuals who...

at 14:15
Gracell Biotechnologies Inc. ("Gracell" or the...

at 14:15
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first-ever results from the Phase 1b RedirecTT-1 study of TECVAYLI® (teclistamab-cqyv), a first-in-class BCMAxCD3 bispecific antibody, and talquetamab, a first-in-class...

at 13:35
Gilead Sciences, Inc. and Arcus Biosciences, Inc. today announced updated results from an interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ?50%...

at 12:17
Sanctuary Cannabis, a trusted provider of high-quality medical cannabis products, is excited to announce the grand opening of its 19th medical cannabis dispensary in Boynton Beach, Florida....

at 12:00
?  PRGN-2009 combined with an investigational checkpoint inhibitor resulted in a 30% ORR in patients with heavily pre-treated HPV-associated cancers that were naïve or resistant to checkpoint blockade with prolonged duration of responses?? ? ...

News published on and distributed by: